Waltham-based Syndax Pharmaceuticals Raises $6M
From New England Tech Wire | Aug 11, 2010
Waltham, Mass. -- Syndax Pharmaceuticals, a Waltham-based epigenetics oncology company, announced on Wednesday that it has raised $6 million in convertible debt from a group of its existing investors, including Domain Associates, MPM Capital, Avalon Ventures, Forward Ventures, Pappas Ventures and MC Life Sciences. Founded in 2005, Syndax’s intellectual property is based on work from its scientific founder Ronald Evans, recipient of the 2004 Albert Lasker Prize for Basic Medical Research and a member of the National Academy of Sciences. The company is building a portfolio of new oncology products and therapies in “optimized, mechanistically driven combination regimens.” Syndax has now raised a total of $55 million.
http://www.syndax.com/
| Topic | Replies | Likes | Views | Participants | Last Reply |
|---|---|---|---|---|---|
| Be Self-Employed Writing Content | 0 | 0 | 302 | ||
| Work from Home Writing Articles | 0 | 0 | 129 | ||
| Band Together Seeks New Executive Director in Raleigh Area | 0 | 0 | 534 |